FDA Inspection Gave Beleaguered GVK Bio Plant Clean Bill of Health

A recent FDA inspection of contract research organization GVK Biosciences’ Hyderabad, India, plant turned up no evidence of safety or efficacy concerns with U.S.-bound generic therapies, a finding that is in sharp contrast to initial conclusions reached by European inspectors.
Drug Industry Daily